<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Drug Investig</journal-id><journal-id journal-id-type="iso-abbrev">Clin Drug Investig</journal-id><journal-title-group><journal-title>Clinical Drug Investigation</journal-title></journal-title-group><issn pub-type="ppub">1173-2563</issn><issn pub-type="epub">1179-1918</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25910606</article-id><article-id pub-id-type="pmc">4449384</article-id><article-id pub-id-type="publisher-id">288</article-id><article-id pub-id-type="doi">10.1007/s40261-015-0288-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Comment on: Incidence and Risk of Hypertension with Ramucirumab in Cancer Patients: A Meta-Analysis of Published Studies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sashegyi</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lin</surname><given-names>Yong</given-names></name><address><email>lin_yong@lilly.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ferry</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Melemed</surname><given-names>Allen</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Eli Lilly and Company, Indianapolis, IN USA </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>35</volume><issue>6</issue><fpage>405</fpage><lpage>405</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>A meta-analysis by Wang et al. [<xref ref-type="bibr" rid="CR1">1</xref>] assessing hypertension risk with ramucirumab use in patients with cancer was recently published in <italic>Clinical Drug Investigation</italic>. The authors concluded that ramucirumab treatment was associated with a significant increase in hypertension risk in cancer patients, and warned that treatment efficacy may be reduced due to the need to manage hypertension.</p><p>We acknowledge hypertension as an adverse reaction for ramucirumab. This is highlighted in the compound&#x02019;s package insert. However, the presentation by Wang et al. of the clinical severity of these events is misleading.</p><p>An analysis of pooled data was performed across six Phase III trials (ramucirumab <italic>N</italic>&#x000a0;=&#x000a0;2748, placebo <italic>N</italic>&#x000a0;=&#x000a0;2248). In this analysis, 21.3&#x000a0;% (<italic>n</italic>&#x000a0;=&#x000a0;585) of patients taking ramucirumab experienced hypertension of any grade during treatment, versus 7.4&#x000a0;% (<italic>n</italic>&#x000a0;=&#x000a0;167) for patients taking placebo. This translates to an increase of 13.9&#x000a0;% in the number of patients developing any grade hypertension, or about 1 in 7. More severe hypertension (&#x02265;Grade 3) was seen in 9&#x000a0;% (<italic>n</italic>&#x000a0;=&#x000a0;246) of patients taking ramucirumab, and 2.5&#x000a0;% (<italic>n</italic>&#x000a0;=&#x000a0;57) of patients taking placebo, a 6.5&#x000a0;% increase, or approximately 1 in 15 patients. These percentages coincide relatively well with the data stated in the Wang et al. meta-analysis. However, of those patients experiencing hypertension, only eight cases (&#x0003c;2&#x000a0;%) led to discontinuation of any study treatment, showing that the hypertension was manageable.</p><p>These additional data suggest that although hypertension is a recognized adverse event in ramucirumab clinical trials, it was manageable and resulted in low rates of discontinuation across six multinational clinical phase 3 trials. Therefore, the suggestion by Wang et al. that hypertension can have an effect on treatment efficacy is unsupported by data.
</p></body><back><ack><p>Writing support was provided by Eli Lilly and Company. A.S., Y.L., D.F. and A.M. are employees of Eli Lilly and Company and hold stocks.</p></ack><ref-list id="Bib1"><title>Reference</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>Incidence and risk of hypertension with ramucirumab in cancer patients: a meta-analysis of published studies</article-title><source>Clin Drug Investig</source><year>2015</year><volume>35</volume><fpage>221</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1007/s40261-015-0272-z</pub-id><pub-id pub-id-type="pmid">25697774</pub-id></element-citation></ref></ref-list></back></article>